OC
CLPT icon

Oppenheimer & Co’s ClearPoint Neuro CLPT Stock Holding History

Oppenheimer & Co’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.5K Buy
+10,600
New +$134K ﹤0.01% 1644
2024
Q4 		– Sell
-13,929
Closed -$156K – 1564
2024
Q3 		$156K Buy
+13,929
New +$133K ﹤0.01% 1431

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Oppenheimer & Co's CLPT Position: Q1 2026 in Review

Oppenheimer & Co opened a new position in ClearPoint Neuro (CLPT) in Q1 2026: 10,600 shares worth $96.5K. The stake represents ﹤0.01% of the portfolio and ranks #1644 among its holdings. This is a return to the name: Oppenheimer & Co previously reported a position in CLPT as recently as Q3 2024.

Oppenheimer & Co first reported a position in CLPT in Q3 2024 and has held it in 2 quarters since. The position peaked at $156K in Q3 2024. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

  • Oppenheimer & Co held 10,600 shares of ClearPoint Neuro worth $96.5K as of Q1 2026.
  • ClearPoint Neuro was a new Oppenheimer & Co position in Q1 2026.
  • ClearPoint Neuro made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1644 holding.
  • Oppenheimer & Co first reported a position in ClearPoint Neuro in Q3 2024 and has held it in 2 quarters since.
  • Oppenheimer & Co's ClearPoint Neuro position peaked at $156K in Q3 2024.
  • 118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.